Swedish Orphan Biovitrum (BIOVF) (SWOBY), the Nordic pharma company also known as Sobi, announced on Friday that the European Commission approved its blood disorder therapy. Aspaveli is marketed with Apellis Pharmaceuticals (APLS) for two rare kidney diseases.
